Genetic and Pathogenic Overlaps Between Autism Spectrum Disorder and Alzheimer’s Disease: Evolutionary Features and Opportunities for Drug Repurposing
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262010066 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ekaterina A Trifonova und 4 weiteren Autor:innen. Beteiligte Einrichtung: Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia. Hauptthemen laut MEDLINE: Autism Spectrum Disorder, Alzheimer Disease, Drug Repositioning. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science.
Themen: Demenz
Abstract (Originalsprache)
Autism spectrum disorder (ASD) and Alzheimer’s disease (AD) are neurodevelopmental and neurodegenerative disorders, respectively. While exome sequencing is routinely employed during the early stages of ASD diagnosis, it rarely influences therapeutic strategies. To address this gap, we have reconstructed and analyzed the gene networks linking autism spectrum disorders, Alzheimer’s disease, and mTOR signaling. In addition, we have performed a phylostratigraphic analysis that reveals similarities and differences in the evolution of both ASD and Alzheimer’s disease predisposition genes. We have shown that almost half of the genes predisposing to autism and two-fifths of the genes predisposing to Alzheimer’s disease are directly related to the mTOR signaling pathway. Analysis of Phylostratigraphic Age Index (PAI) value distributions revealed a significant enrichment of evolutionarily ancient genes in both ASD- and AD-related gene sets. When studying the distribution of ASD predisposition genes by Divergence Index (DI) values, a significant enrichment with genes having extremely low DI = 0 has been found. Such low DI values indicate that most likely these genes are under stabilizing selection. Using the ANDVisio tool, both pharmacological and natural mTOR regulators with potential for ASD treatment were selected, such as propofol, dexamethasone, celecoxib, statins, berberine, resveratrol, quercetin, myricetin, mio-inositol, and several amino acids.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
- Natural Science Faculty, Novosibirsk National Research State University, 630090 Novosibirsk, Russia.
ORCID-Profile: Ekaterina A Trifonova, Roman A Ivanov, Alex V Kochetov, Sergey A Lashin
Förderung
- Ministry of Science
Zitieren
APA
Trifonova, E. A., Pashchenko, A. A., Ivanov, R. A., Kochetov, A. V., & Lashin, S. A. (2025). Genetic and Pathogenic Overlaps Between Autism Spectrum Disorder and Alzheimer’s Disease: Evolutionary Features and Opportunities for Drug Repurposing. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262010066
Vancouver
Trifonova EA, Pashchenko AA, Ivanov RA, Kochetov AV, Lashin SA. Genetic and Pathogenic Overlaps Between Autism Spectrum Disorder and Alzheimer’s Disease: Evolutionary Features and Opportunities for Drug Repurposing. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262010066
BibTeX
@article{Trifonova2025,
author = {Trifonova, Ekaterina A and Pashchenko, Anna A and Ivanov, Roman A and Kochetov, Alex V and Lashin, Sergey A},
title = {Genetic and Pathogenic Overlaps Between Autism Spectrum Disorder and Alzheimer’s Disease: Evolutionary Features and Opportunities for Drug Repurposing},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262010066}
}
EUVIMED